Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 33, Issue 4, p.364-9 (2015)


Adolescent, Adult, Aged, Antineoplastic Agents, Bone Marrow Transplantation, Female, Graft vs Host Disease, Hematologic Neoplasms, Humans, Immunosuppressive Agents, Male, methotrexate, Middle Aged, Multivariate Analysis, Mycophenolic Acid, Outcome Assessment (Health Care), Peripheral Blood Stem Cell Transplantation, Proportional Hazards Models, Survival Analysis, Transplantation Conditioning, Unrelated Donors, Vidarabine, Young Adult


There have been no randomized trials that have compared peripheral blood (PB) with bone marrow (BM) grafts in the setting of reduced-intensity conditioning (RIC) transplantations for hematologic malignancy. Because immune modulation plays a significant role in sustaining clinical remission after RIC, we hypothesize that higher graft-versus-host disease (GVHD) associated with PB transplantation may offer a survival advantage.